Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 14, 2020 07:01 ET | Source: 89bio, Inc.

89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
August 03, 2020 16:05 ET | Source: 89bio, Inc.

89bio to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
July 06, 2020 06:30 ET | Source: 89bio, Inc.

89bio Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
May 13, 2020 16:05 ET | Source: 89bio, Inc.

89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 - - Announces FDA Clearance of BIO89-100 IND Application for SHTG - SAN FRANCISCO, May 13, 2020 (GLOBE NEWSWIRE)...
April 13, 2020 08:30 ET | Source: 89bio, Inc.

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism

- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in...
March 25, 2020 16:05 ET | Source: 89bio, Inc.

89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors

SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
March 18, 2020 16:05 ET | Source: 89bio, Inc.

89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:...
February 21, 2020 16:05 ET | Source: 89bio, Inc.

89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
December 18, 2019 16:05 ET | Source: 89bio, Inc.

89bio Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Upsized Initial Public Offering raises $97.6 million in gross proceeds - - BIO89-100 continues to advance in Phase 1b/2a NASH study - SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc....
November 13, 2019 16:02 ET | Source: 89bio, Inc.

89bio Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO and HERZLIYA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...

Next Page keyboard_arrow_right